The DOI matches its OpenAlex record; 38 of the 38 references it cites were found in a registry or an index.
Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment
Open accessAbstract
Glioblastoma multiforme (GBM) is one of the most malignant types of central nervous system tumors. Despite advances in treatment modalities it remains largely incurable. The objective of our review is to provide a holistic picture of GBM epidemiology, etiology, pathogenesis, clinical findings and treatment. A literature search was conducted for GBM at PubMed and Google Scholar, with relevant key words like glioblastoma multiforme, pathogenesis, signs and symptoms, treatment etc., and papers published until 2015 were reviewed. It was found that radiation and certain genetic syndromes are the only risk factors identified to date for GBM. Depending on the tumor site patients may present to the clinic with varying symptoms. To confirm the presence and the extent of tumor, various invasive and non-invasive imaging techniques require employment. The literature survey revealed the pathogenesis to involve aberrations of multiple signaling pathways through multiple genetic mutations and altered gene expression. Although several treatment options are available, including surgery, along with adjuvant chemo- and radio-therapy, the disease has a poor prognosis and patients generally succumb within 14 months of diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Glioblastoma and Other Malignant Gliomas: A Clinical Review
Omuro, A. (2013) · JAMA · doi:10.1001/jama.2013.280319 · Cited by 2,301
Genetic Pathways to Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070011 · Cited by 1,497
Epidemiologic and Molecular Prognostic Review of Glioblastoma
Thakkar, J. P., Dolecek, T. A., Horbinski, C., Ostrom, Q. T., Lightner, D. D., Barnholtz-Sloan, J. S., & Villano, J. L. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0275 · Cited by 1,390
Epidemiology and etiology of gliomas
Ohgaki, H., & Kleihues, P. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-0991-y · Cited by 1,252
Malignant glioma: genetics and biology of a grave matter
Maher, E. A., Furnari, F. B., Bachoo, R. M., Rowitch, D. H., Louis, D. N., Cavenee, W. K., & DePinho, R. A. (2001) · Genes & Development · doi:10.1101/gad.891601 · Cited by 1,229
The Definition of Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3002 · Cited by 1,132
Epidemiology and molecular pathology of glioma
Schwartzbaum, J. A., Fisher, J. L., Aldape, K. D., & Wrensch, M. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0289 · Cited by 949
Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium
Bondy, M. L., Scheurer, M. E., Malmer, B., Barnholtz-Sloan, J. S., Davis, F. G., Il'yasova, D., Kruchko, C., McCarthy, B. J., Rajaraman, P., Schwartzbaum, J. A., et al. (2008) · Cancer · doi:10.1002/cncr.23741 · Cited by 932
Epidemiology of primary brain tumors: Current concepts and review of the literature
Wrensch, M., Minn, Y., Chew, T., Bondy, M., & Berger, M. S. (2002) · Neuro-Oncology · doi:10.1093/neuonc/4.4.278 · Cited by 837
Glioblastoma multiforme: The terminator
Holland, E. C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6242 · Cited by 762
Glioblastoma: pathology, molecular mechanisms and markers
Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G., & von Deimling, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1432-1 · Cited by 735
Temozolomide and treatment of malignant glioma
Friedman, H. S., Kerby, T., & Calvert, H. (2000) · PubMed · doi:10.25405/ncl.34644405 · Cited by 731
Glioblastoma multiforme: a review of where we have been and where we are going
Adamson, C., Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Mattox, A. K., & Bigner, D. D. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903052764 · Cited by 550
Fisher, J. L., Schwartzbaum, J. A., Wrensch, M., & Wiemels, J. L. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.07.002 · Cited by 528
Glioblastoma: From Molecular Pathology to Targeted Treatment
Cloughesy, T. F., Cavenee, W. K., & Mischel, P. S. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130324 · Cited by 518
Cellular-Telephone Use and Brain Tumors
Inskip, P. D., Tarone, R. E., Hatch, E. E., Wilcosky, T. C., Shapiro, W. R., Selker, R. G., Fine, H. A., Black, P. M., Loeffler, J. S., & Linet, M. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101113440201 · Cited by 483
Liu, X.-Y., Gerges, N., Korshunov, A., Sabha, N., Khuong-Quang, D.-A., Fontebasso, A. M., Fleming, A., Hadjadj, D., Schwartzentruber, J., Majewski, J., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1031-3 · Cited by 428
Ohgaki, H. (2009) · Methods in Molecular Biology · doi:10.1007/978-1-60327-492-0_14 · Cited by 418
Atopy and Risk of Brain Tumors: A Meta-analysis
Linos, E., Raine, T., Alonso, A., & Michaud, D. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm170 · Cited by 275
Agnihotri, S., Burrell, K. E., Wolf, A., Jalali, S., Hawkins, C., Rutka, J. T., & Zadeh, G. (2013) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0203-0 · Cited by 272
Aberrant Signaling Pathways in Glioma
Nakada, M., Kita, D., Watanabe, T., Hayashi, Y., Teng, L., Pyko, I. V., & Hamada, J.-I. (2011) · Cancers · doi:10.3390/cancers3033242 · Cited by 264
Reardon, D. A., & Wen, P. Y. (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-152 · Cited by 231
Current data and strategy in glioblastoma multiforme.
Iacob, G., & Dinca, E. B. (2009) · PubMed Central · Cited by 225
Advances and challenges in the treatment of glioblastoma: a clinician's perspective.
Mrugała, M. M. (2013) · PubMed · Cited by 203
Current Trends in Targeted Therapies for Glioblastoma Multiforme
Ohka, F., Natsume, A., & Wakabayashi, T. (2012) · Neurology Research International · doi:10.1155/2012/878425 · Cited by 200
Rock, K., Mcardle, O., Forde, P., Dunne, M., Fitzpatrick, D., O'Neill, B., & Faul, C. (2012) · The British Journal of Radiology · doi:10.1259/bjr/83796755 · Cited by 199
Glioma and glioblastoma - how much do we (not) know?
JOVČEVSKA, I., KOČEVAR, N., & KOMEL, R. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.172 · Cited by 180
Norden, A. D., & Wen, P. Y. (2006) · The Neurologist · doi:10.1097/01.nrl.0000250928.26044.47 · Cited by 159
Salvati, M., Frati, A., Russo, N., et al. (2003) · Surgical Neurology · doi:10.1016/s0090-3019(03)00137-x · Cited by 156
Understanding Glioblastoma Tumor Biology: The Potential to Improve Current Diagnosis and Treatments
Kesari, S. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.09.005 · Cited by 143
Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy
Sengupta, S., Marrinan, J. E., Frishman, C., & Sampath, P. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/831090 · Cited by 129
Do Steroid Hormones Play a Role in the Etiology of Glioma?
Kabat, G. C., Etgen, A. M., & Rohan, T. E. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0658 · Cited by 121
Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme.
Chang, J. E., Khuntia, D., Robins, H. I., & Mehta, M. P. (2007) · PubMed · Cited by 112
Strategy for surveying the proteome using affinity proteomics and mass spectrometry
Wingren, C., James, P., & Borrebaeck, C. A. K. (2009) · PROTEOMICS · doi:10.1002/pmic.200800802 · Cited by 85
Messali, A. J., Villacorta, R., & Hay, J. W. (2014) · PharmacoEconomics · doi:10.1007/s40273-014-0198-y · Cited by 64
Cited by
Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges
Zhang, W., Mehta, A., Tong, Z., Esser, L., & Voelcker, N. H. (2021) · Advanced Science · doi:10.1002/advs.202003937 · Cited by 430
Nguyen, V., Taine, E. G., Meng, D., Cui, T., & Tan, W. (2024) · Nutrients · doi:10.3390/nu16070924 · Cited by 378
EGFR signaling pathway as therapeutic target in human cancers
Levantini, E., Maroni, G., Del Re, M., & Tenen, D. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.002 · Cited by 356
Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
Yalamarty, S. S. K., Filipczak, N., Li, X., Subhan, M. A., Parveen, F., Ataide, J. A., Rajmalani, B. A., & Torchilin, V. P. (2023) · Cancers · doi:10.3390/cancers15072116 · Cited by 293
Pouyan, A., Ghorbanlo, M., Eslami, M., Jahanshahi, M., Ziaei, E., Salami, A., Mokhtari, K., Shahpasand, K., Farahani, N., Meybodi, T. E., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02267-0 · Cited by 271
Metadata
- Authors
- Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M., & Sımjee, S. U.
- Venue
- PubMed
- Publisher
- National Institutes of Health
- Published
- 2017-01-01
- Volume
- 18
- Issue
- 1
- Pages
- 3-9
- OpenAlex
- W2584466409
- Cited by
- 1,231
- References
- 38
- FWCI
- 29.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.